Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label

S Lindbo, J Garousi, B Mitran, M Altai… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Visualization of cancer-associated alterations of molecular phenotype using radionuclide
imaging is a noninvasive approach to stratifying patients for targeted therapies. The …

Influence of the N-terminal composition on targeting properties of radiometal-labeled anti-HER2 scaffold protein ADAPT6

J Garousi, S Lindbo, H Honarvar, J Velletta… - Bioconjugate …, 2016 - ACS Publications
Radionuclide-imaging-based stratification of patients to targeted therapies makes cancer
treatment more personalized and therefore more efficient. Albumin-binding domain derived …

Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer

O Bragina, E von Witting, J Garousi… - Journal of nuclear …, 2021 - Soc Nuclear Med
Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2)
expression may help to stratify breast and gastroesophageal cancer patients for HER2 …

[HTML][HTML] Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m

J Garousi, S Lindbo, B Mitran, J Buijs, A Vorobyeva… - Scientific reports, 2017 - nature.com
Abstract ABD-Derived Affinity Proteins (ADAPTs) is a novel class of engineered scaffold
proteins derived from an albumin-binding domain of protein G. The use of ADAPT6 …

Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga

S Lindbo, J Garousi, B Mitran, A Vorobyeva… - Molecular …, 2018 - ACS Publications
Radionuclide molecular imaging is a promising tool for visualization of cancer associated
molecular abnormalities in vivo and stratification of patients for specific therapies. ADAPT is …

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting Affibody molecule–albumin-binding domain fusion protein

A Orlova, A Jonsson, D Rosik, H Lundqvist… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Because of their better penetration, smaller targeting proteins may be superior to antibodies
for radioimmunotherapy of solid tumors. Therefore, Affibody molecules (6.5 kDa) have a …

[HTML][HTML] Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle

J Garousi, E von Witting, J Borin, A Vorobyeva, M Altai… - Biomaterials, 2021 - Elsevier
Molecular recognition in targeted therapeutics is typically based on immunoglobulins.
Development of engineered scaffold proteins (ESPs) has provided additional opportunities …

[HTML][HTML] Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours

J Garousi, S Lindbo, J Borin, E von Witting… - European journal of …, 2019 - Elsevier
ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have
demonstrated very promising features as vectors for radionuclide tumour targeting …

[HTML][HTML] Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein …

E von Witting, J Garousi, S Lindbo, A Vorobyeva… - European journal of …, 2019 - Elsevier
Radionuclide molecular imaging is a promising tool that becomes increasingly important as
targeted cancer therapies are developed. To ensure an effective treatment, a molecular …

ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers

J Garousi, S Lindbo, J Nilvebrant, M Åstrand, J Buijs… - Cancer research, 2015 - AACR
Small engineered scaffold proteins have attracted attention as probes for radionuclide-
based molecular imaging. One class of these imaging probes, termed ABD-Derived Affinity …